Home > Drugs A – Z > Prasugrel (By mouth)

Prasugrel (By mouth)

Prevents blood clots, which can lead to heart attack, in patients who need to have percutaneous coronary intervention (PCI).

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Prasugrel is used to prevent strokes, heart attacks, or other serious problems with your heart or blood vessels. It is given to patients before they have a heart procedure called percutaneous coronary intervention (PCI). A heart attack or stroke may occur when a blood vessel in the heart or brain is blocked by a blood clot. Prasugrel reduces the chance that a harmful blood clot will form by… Read more
Brand names include
Effient
Drug classes About this
Platelet Aggregation Inhibitor

What works? Research summarized

Evidence reviews

Addendum to Commission A09-02 (Prasugrel for Acute Coronary Syndrome) [Internet]

In its letter of September 15, 2011, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to provide further information about the Final Report A09-02 (Prasugrel for acute coronary syndrome (ACS)). Information was requested about the H7T-MC-TACM study mentioned on Page 130 of the Final Report, particularly a specific description of the study design and an answer to the question whether the H7T-MC-TACM study has effects on the assessment, already undertaken by IQWiG, of clopidogrel plus acetylsalicylic acid (ASA) in ACS (A04-01B).

A Systematic Review and Economic Evaluation of Prasugrel Compared to Clopidogrel After PCI [Internet]

A systematic review and economic evaluation of prasugrel compared to clopidogrel after PCI Patients who have undergone percutaneous coronary intervention (PCI) for coronary artery disease usually get a platelet inhibitor (e.g. clopidogrel) for one year after the procedure. Prasugrel is a new platelet inhibitor which is available for patients with acute coronary syndrome (ACS) who undergo PCI in Norway.

Prasugrel for acute coronary syndrome: Executive summary of final report A09-02, Version 1.0

The aim of this investigation was to assess the benefit of combination therapy comprising prasugrel plus ASA in patients with ACS undergoing primary or delayed PCI. In patients with unstable angina /NSTEMI the assessment was to be conducted in comparison with combination therapy comprising clopidogrel plus ASA, or with monotherapy comprising ASA with or without prior dual antiplatelet therapy. The focus of the assessment was on patient-relevant outcomes. Due to the approval status of clopidogrel, in patients with STEMI the assessment was only to be performed versus ASA monotherapy. The results were to be analysed separately for patients with unstable angina /NSTEMI and those with STEMI.

See all (47)

Summaries for consumers

Comparing Newer Antiplatelet Agents

How do antiplatelet agents compare in acute coronary syndromes managed medically?

What is anti-clotting medication and how is it used safely?

Anti-clotting medication is used to prevent blood clots from forming, and therefore lower the risk of certain cardiovascular diseases like heart attacks and strokes. As the name suggests, they make sure that the blood does not clot as quickly.

Antiplatelet agents and anticoagulants for hypertension

Daily aspirin reduces the incidence of heart attacks to a small degree, but increases the incidence of major bleeding events to a similar degree in patients treated for high blood pressure who have not had a prior stroke or heart attack. In patients with high blood pressure who have had a stroke or heart attack, the benefits of daily low‐dose aspirin outweigh the harms. There is no evidence of benefit for antithrombotic therapy with warfarin alone or in combination with aspirin in patients with high blood pressure. The benefits and harms of the newer drugs glycoprotein IIb/IIIa inhibitors, clopidogrel, prasugrel, ticagrelor and oral antithrombotic agents such as dabigatran and rivaroxaban for patients with high blood pressure have not been studied in clinical trials.

See all (5)

PubMed Health Blog...

read all...